Fennec Pharmaceuticals 경영진
경영진 기준 점검 3/4
Fennec Pharmaceuticals CEO는 Jeff Hackman, Aug2024 에 임명되었습니다 의 임기는 1.75 년입니다. 총 연간 보상은 $1.72M, 34% 급여 및 66% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $612.34K 가치에 해당하는 회사 주식의 0.18% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 1.7 년과 10.9 년입니다.
핵심 정보
Jeff Hackman
최고경영자
US$1.7m
총 보수
| CEO 급여 비율 | 34.05% |
| CEO 재임 기간 | 1.8yrs |
| CEO 지분 보유율 | 0.2% |
| 경영진 평균 재임 기간 | 1.7yrs |
| 이사회 평균 재임 기간 | 10.9yrs |
최근 경영진 업데이트
Recent updates
분석 기사 • May 17
We're Not Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
내러티브 업데이트 • May 14
FENC: Expanding Cisplatin Ototoxicity Protection Use Will Support Future Bullish Earnings Multiple
Analysts have maintained their $18.00 price target on Fennec Pharmaceuticals, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that leave their overall valuation view unchanged. What's in the News Four abstracts on PEDMARK are set to be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, focusing on cisplatin related hearing loss and real world outcomes in patients receiving platinum based chemotherapy (Key Developments).내러티브 업데이트 • Apr 25
FENC: Expanding Cisplatin Ototoxicity Use Should Support Future Bullish Earnings Multiple
Analysts have adjusted their price target on Fennec Pharmaceuticals to $18.00, with the change supported by updated assumptions around revenue growth, profit margins, and a future P/E of about 12.8, in line with a recently bullish initiation from Street research. Analyst Commentary Bullish analysts are framing the updated US$18.00 price target as consistent with expectations for Fennec Pharmaceuticals to execute against current revenue and margin assumptions while trading on a P/E of about 12.8. These views generally point to a setup where, if the company delivers on its plan, the current valuation case remains intact and could support the new target level.내러티브 업데이트 • Apr 10
FENC: Cisplatin Ototoxicity Niche Will Support Future Bullish Earnings Multiple
Analysts have raised their price target on Fennec Pharmaceuticals to $18.00, supported by updated assumptions on revenue growth, profit margin and future P/E, and underpinned by a recent bullish initiation from B. Riley that reflects growing confidence in the company’s outlook.내러티브 업데이트 • Mar 27
FENC: Cisplatin Ototoxicity Niche Will Underpin Future Supportive Care Upside
Analysts have reaffirmed an $18 price target for Fennec Pharmaceuticals, highlighting supportive research that emphasizes Pedmark's role as a unique, approved option in oncology supportive care. They are also reassessing assumptions related to future revenue growth, profit margins and P/E expectations.
내러티브 업데이트 • Mar 11
FENC: Single Oncology Supportive Care Asset Will Drive Future Upside Potential
Narrative Update: Fennec Pharmaceuticals Analysts have lifted their price target on Fennec Pharmaceuticals from $14.00 to about $15.33, citing a richer revenue outlook, higher anticipated profit margins, and a willingness to apply a lower future P/E multiple. They highlight Pedmark's position as a unique, FDA approved option in oncology supportive care, with U.S. peak sales potential referenced above $300m.내러티브 업데이트 • Feb 25
FENC: Cisplatin Ototoxicity Niche Will Support Future Oncology Care Upside
Analysts are reiterating an $18 price target for Fennec Pharmaceuticals. They point to updated assumptions that include slightly lower discount rates, higher projected revenue growth and profit margins, and a modestly lower future P/E, supported by recent bullish initiations that highlight Pedmark's role as a unique oncology supportive care opportunity.내러티브 업데이트 • Feb 10
FENC: Cisplatin Ototoxicity Niche Will Drive Future Supportive Care Upside
Analysts have reiterated a US$18 price target on Fennec Pharmaceuticals, supported by their view that Pedmark offers a unique, only-approved option in oncology supportive care, with what they describe as realistic peak U.S. sales potential above US$300m. Analyst Commentary Recent coverage has centered on Pedmark as a key driver for Fennec's equity story, with bullish analysts highlighting its role as the only approved agent for reducing the risk of cisplatin induced ototoxicity in oncology supportive care.내러티브 업데이트 • Jan 26
FENC: Cisplatin Ototoxicity Leadership And New Studies Will Support Strong Future Upside
Narrative Update Analysts are reaffirming a US$18 price target on Fennec Pharmaceuticals, pointing to Pedmark's role as the only approved agent for reducing cisplatin induced ototoxicity and noting that they view U.S. peak sales potential above US$300m as realistic. Analyst Commentary Bullish analysts are highlighting Fennec Pharmaceuticals as a focused oncology supportive care story, built around Pedmark as an intravenous formulation of sodium thiosulfate for reducing the risk of cisplatin induced ototoxicity.내러티브 업데이트 • Jan 12
FENC: Unique Oncology Supportive Care Opportunity Will Drive Stronger Future Upside Potential
Narrative Update Overview Our fair value estimate for Fennec Pharmaceuticals edges up from $17 to $18 per share, reflecting analysts' view that Pedmark offers a unique oncology supportive care opportunity with U.S. peak sales potential cited north of $300 million and supports using a slightly higher revenue growth outlook, modestly stronger profit margins, and a lower future P/E multiple. Analyst Commentary Bullish analysts are centering their thesis on Pedmark as a differentiated oncology supportive care product, and that view is shaping how they think about valuation, execution risk, and long term growth potential.내러티브 업데이트 • Dec 27
FENC: Expanded Adult Study Will Drive Stronger Future Upside Potential
Analysts have nudged their price target on Fennec Pharmaceuticals modestly higher to reflect slightly faster expected revenue growth, marginally improved profit margins, and a marginally lower projected future price to earnings multiple, supporting a fair value estimate of $17.00 per share. What's in the News Planned City of Hope investigator sponsored study will evaluate PEDMARK for preventing cisplatin induced hearing loss in adult men with stage II III metastatic testicular germ cell tumors, expanding its potential use beyond pediatrics (company announcement).Seeking Alpha • Dec 22
Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026
Summary Fennec Pharmaceuticals is a commercial-stage oncology supportive-care company centered on Pedmark/Pedmarqsi. This drug helps reduce cisplatin-induced ototoxicity in pediatric patients who are battling cancer. Pedmark is FDA-approved for pediatric patients ≥1 month, and it has shown good efficacy so far with patients. Pedmark is also the “first/only” in this drug class, and management believes they can eventually make Pedmark the standard-of-care to avoid hearing loss. Thus, despite FENC’s concentrated risk on Pedmark, I feel their outlook for 2026 is quite compelling. So, I rate the stock a “Buy” at these levels. Read the full article on Seeking Alpha내러티브 업데이트 • Dec 13
FENC: Expanded Hearing Loss Indication Will Drive Stronger Future Upside Potential
Analysts have raised their price target on Fennec Pharmaceuticals from 15 dollars to 17 dollars, citing updated assumptions for discount rates, growth, profitability, and valuation multiples that, despite being more conservative on margins and revenue growth, still imply a higher fair value. What's in the News City of Hope to launch an investigator sponsored study of PEDMARK in adult men with stage II III metastatic testicular germ cell tumors to prevent cisplatin induced hearing loss, expanding potential use beyond pediatrics (company announcement) Positive topline results reported from the Phase 2/3 STS J01 trial in Japan evaluating PEDMARK for reducing cisplatin induced ototoxicity in pediatric and AYA patients, with Fennec planning to pursue Japanese registration and potential partnering or licensing deals (company announcement) Completed 35 million dollar follow on equity offering of 4,666,667 common shares at 7.50 dollars per share, bolstering the balance sheet for commercialization and development initiatives (financing filing) Announced a non brokered private placement of 670,000 common shares at 7.50 dollars per share for expected gross proceeds of 5.0 million dollars, with closing targeted for November 17, 2025 (financing announcement) Lock up agreements put in place on over 28 million common shares and various equity linked awards through February 12, 2026, limiting insider and holder sales for 91 days after the November 13, 2025 offering (offering documentation) Valuation Changes Fair value estimate increased from 15 dollars to 17 dollars per share, implying a modest upward revision to intrinsic value despite more conservative operating assumptions.분석 기사 • Apr 24
Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price Is Matching Sentiment Around Its Revenues
With a price-to-sales (or "P/S") ratio of 3.3x Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) may be sending very bullish...분석 기사 • Mar 13
US$12.60: That's What Analysts Think Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Is Worth After Its Latest Results
Shareholders might have noticed that Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) filed its full-year result this time...분석 기사 • Nov 24
Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified
Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) shareholders are no doubt pleased to see that the share price has bounced...분석 기사 • Oct 04
Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price
You may think that with a price-to-sales (or "P/S") ratio of 2.5x Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) is...
새로운 내러티브 • Sep 28
Jeff Hackman's Leadership And PEDMARK's Launch Promise Robust Revenue Surge
Introduction of PEDMARK and strategic partnerships aim to boost net revenues through expanded patient access and improved distribution.분석 기사 • Aug 15
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be
Today is shaping up negative for Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) shareholders, with the analysts delivering...분석 기사 • Jul 16
Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Jun 02
Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop
The Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) share price has fared very poorly over the last month, falling by a...분석 기사 • Apr 18
Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
With a median price-to-sales (or "P/S") ratio of close to 12.9x in the Biotechs industry in the United States, you...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$8m |
| Dec 31 2025 | US$2m | US$586k | -US$10m |
| Sep 30 2025 | n/a | n/a | -US$7m |
| Jun 30 2025 | n/a | n/a | -US$12m |
| Mar 31 2025 | n/a | n/a | -US$14m |
| Dec 31 2024 | US$2m | US$225k | -US$436k |
보상 대 시장: Jeff의 총 보수(USD1.72M)는 US 시장에서 비슷한 규모 기업의 평균(USD2.64M)보다 낮습니다.
보상과 수익: Jeff의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Jeff Hackman (62 yo)
1.8yrs
재임 기간
US$1,722,154
보수
Mr. Jeffrey S. Hackman, also known as Jeff, is CEO & Director of Fennec Pharmaceuticals Inc. from August 16, 2024. He served as Chairman, President and Chief Executive Officer of Comera Life Sciences Holdi...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$1.72m | 0.18% $ 612.3k | |
| Chief Financial Officer | 10.5yrs | US$1.87m | 0.83% $ 2.9m | |
| Chief Medical Officer | 1.6yrs | US$775.08k | 0.060% $ 207.0k | |
| Chief Commercial Officer | 1.6yrs | 데이터 없음 | 0.060% $ 207.0k | |
| Chief Strategy Officer | 1.6yrs | 데이터 없음 | 0.069% $ 238.5k | |
| Controller | 10.5yrs | 데이터 없음 | 데이터 없음 | |
| President of Pharstat Inc | no data | 데이터 없음 | 데이터 없음 |
1.7yrs
평균 재임 기간
경험이 풍부한 관리: FENC의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 1.7 년) — 신규 팀일 수 있습니다.
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$1.72m | 0.18% $ 612.3k | |
| Independent Director | 14.8yrs | US$173.72k | 0.18% $ 626.3k | |
| Independent Chairman of the Board | 12.1yrs | US$214.02k | 0.62% $ 2.1m | |
| Independent Director | 6.7yrs | US$153.72k | 0% $ 0 | |
| Director | 16.8yrs | 데이터 없음 | 0.35% $ 1.2m | |
| Independent Director | 9.8yrs | US$168.72k | 0% $ 0 |
10.9yrs
평균 재임 기간
66yo
평균 나이
경험이 풍부한 이사회: FENC의 이사회는 노련하고 경험이 풍부합니다(평균 재임 10.9 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/26 15:11 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Fennec Pharmaceuticals Inc.는 10명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Naureen Quibria | Capital One Securities, Inc. |